RNA interference technology for anti-VEGF treatment

被引：24

作者：

Chen, Shun ^{[1
,2
]}

Feng, Jia ^{[2
]}

Ma, Liuqing ^{[2
]}

Liu, Zhenguo ^{[1
]}

Yuan, Weien ^{[2
]}

机构：

[1] Shanghai Jiao Tong Univ, Xinhua Hosp Affiliated, Sch Med, Dept Neurol, Shanghai 200092, Peoples R China

[2] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China

来源：

EXPERT OPINION ON DRUG DELIVERY | 2014年 / 11卷 / 09期

基金：

美国国家科学基金会;

关键词：

age-related macular degeneration; angiogenesis; anti-VEGF; gene delivery; RNA interfering; small interfering RNA; tumor; VEGF; ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; MACULAR DEGENERATION; SYSTEMIC DELIVERY; TARGETING VEGF; TUMOR-GROWTH; INTRAVITREAL INJECTION; COMBINATION THERAPY; SPLICE VARIANTS; CELLS SECRETE;

D O I：

10.1517/17425247.2014.926886

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Overexpression of VEGF has been identified to be associated with many pathologic processes such as tumors and retinopathy. Inhibiting uncontrolled growth of VEGF is a promising strategy to treat these diseases. Currently small molecule inhibitors and monoclonal antibodies are the primary treatment. However, complex development, short half-life, limited effectiveness and potential systemic side effects limited their applications. Highly effective and safe therapeutic technologies are highly desirable to meet the growing clinical needs. RNA interference (RNAi) technology, inhibits special gene activity at the post transcriptional level and reduces the expression of relevant proteins, holding great potential due to its easy design and high efficacy. Some molecules based on RNAi have been investigating in different clinical trials. Areas covered: In this article, we review and consider current advances in the application of RNAi technology and potential future clinical strategies. Expert opinion: RNAi technology has a promising future in anti-VEGF treatment, most of the investigations are encouraging and exciting. More anti-VEGF candidates will enter clinical trials and may be a novel therapeutic strategy.

引用

页码：1471 / 1480

页数：10

共 93 条

[1] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].

Achen, MG ;

Jeltsch, M ;

Kukk, E ;

Mäkinen, T ;

Vitali, A ;

Wilks, AF ;

Alitalo, K ;

Stacker, SA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553

[2]

[Anonymous], 2012, B D ADV INF RNA INT

[3] Isolation of putative progenitor endothelial cells for angiogenesis [J].

Asahara, T ;

Murohara, T ;

Sullivan, A ;

Silver, M ;

vanderZee, R ;

Li, T ;

Witzenbichler, B ;

Schatteman, G ;

Isner, JM .

SCIENCE, 1997, 275 (5302) :964-967

[4] The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle [J].

Basset, DL .

AMERICAN JOURNAL OF ANATOMY, 1943, 73 (02) :251-291

[5]

Bates DO, 2002, CANCER RES, V62, P4123

[6] Inhibition of oxygen-induced retinopathy in RTP801-deficient mice [J].

Brafman, A ;

Mett, I ;

Shafir, M ;

Gottlieb, H ;

Damari, G ;

Gozlan-Kelner, S ;

Vishnevskia-Dai, V ;

Skaliter, R ;

Einat, P ;

Faerman, A ;

Feinstein, E ;

Shoshani, T .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (10) :3796-3805

[7] Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes [J].

Brugarolas, J ;

Kaelin, WG .

CANCER CELL, 2004, 6 (01) :7-10

[8] RNAi therapeutics: a potential new class of pharmaceutical drugs [J].

Bumcrot, David ;

Manoharan, Muthiah ;

Koteliansky, Victor ;

Sah, Dinah W. Y. .

NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :711-719

[9] Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].

Carmeliet, P ;

Ferreira, V ;

Breier, G ;

Pollefeyt, S ;

Kieckens, L ;

Gertsenstein, M ;

Fahrig, M ;

Vandenhoeck, A ;

Harpal, K ;

Eberhardt, C ;

Declercq, C ;

Pawling, J ;

Moons, L ;

Collen, D ;

Risau, W ;

Nagy, A .

NATURE, 1996, 380 (6573) :435-439

[10] The promises and pitfalls of RNA-interference-based therapeutics [J].

Castanotto, Daniela ;

Rossi, John J. .

NATURE, 2009, 457 (7228) :426-433

← 1 2 3 4 5 6 7 8 9 10 →